Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy

Details

The goal of Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy is to help you to discern the role of each of the first-line and more novel therapies, including monoclonal antibodies and proteasome, deacetylase, and 3 serine/threonine protein kinase inhibitor therapies in the treatment of multiple myeloma.

By the end of Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy, you will be able to:
• Recall updates in the staging, prognosis, and diagnosis of MM.
• Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
• Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: evidence-based treatment guidelines, algorithms, and expert opinion.
• Summarize the risk-benefit profiles of current and emerging therapies for the treatment of MM.

Target Audience:
Hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with MM.